Dr. Falk Pharma GmbH

Related records

Trials (47)

• 9 mg Budesonide Once Daily (OD) Versus 3 mg Budesonide Three Times Daily (TID) in Active Crohn's Disease
• A Study Evaluating the Efficacy and Safety of ST-0529 in Subjects With Moderately to Severely Active Ulcerative Colitis
• Budesonide 3x3mg/d Versus Prednisone in Active Autoimmune Hepatitis
• Budesonide 9 mg Capsules in Active UC
• Budesonide Capsules Versus Mesalazine Granules in Active Ulcerative Colitis (UC)
• Budesonide Capsules vs. Mesalazine Granules vs. Placebo in Collagenous Colitis
• Budesonide Effervescent Tablets vs. Viscous Budesonide Suspension vs. Placebo in Eosinophilic Esophagitis
• Budesonide Foam Versus Placebo for Prevention of Acute Radiation Proctitis
• Budesonide for Induction of Remission in Incomplete Microscopic Colitis
• Budesonide for Prevention of Acute Gastrointestinal GVHD Following Allogenic Stem Cell Transplantation
• Budesonide Orodispersible Tablet vs. Placebo in Active Eosinophilic Esophagitis
• Budesonide Treatment for Lymphocytic Colitis
• Budesonide Versus Mesalazine Versus Placebo in Lymphocytic Colitis
• Budesonide vs. Mesalazine vs. Budesonide/Mesalazine Suppository Combination Therapy in Acute Ulcerative Proctitis
• Different Doses of Naronapride vs. Placebo in Gastroparesis
• Different Doses of ZED1227 vs. Placebo in NAFLD
• Efficacy and Safety Study of Budesonide to Treat Oral Chronic Graft vs Host Disease (cGvHD)
• Evaluating the Efficacy and Tolerability of ZED1227 in Subjects With Non-responsive Celiac Disease
• Maintenance of Remission With Budesonide Orodispersible Tablets vs. Placebo in Eosinophilic Esophagitis
• Mesalamine for Uncomplicated Diverticular Disease: a Randomized, Double-blind, Placebo-controlled Study